Suppr超能文献

草药补充剂作为治疗新冠肺炎的选择:呼吁对撒哈拉以南非洲新出现和再次出现的病毒威胁进行草药补充剂的临床开发。

Herbal supplements as treatment options for COVID-19: A call for clinical development of herbal supplements for emerging and re-emerging viral threats in Sub-Saharan Africa.

作者信息

Onyeaghala Augustine Anayochukwu, Anyiam Arinze Favour, Husaini Danladi Chiroma, Onyeaghala Emmanuella Ogechi, Obi Ejeatuluchukwu

机构信息

Unit of Clinical Chemistry, Department of Medical Laboratory Science, University College Hospital, Ibadan, Nigeria.

Unit of Clinical Chemistry, Department of Medical Laboratory Science, Chrisland University, Owode, Abeokuta, Ogun State, Nigeria.

出版信息

Sci Afr. 2023 Jul;20:e01627. doi: 10.1016/j.sciaf.2023.e01627. Epub 2023 Mar 5.

Abstract

The advent of Corona virus Disease 2019 (COVID-19) distorted health systems of many countries. Efforts have been made to either develop new treatment solutions such as vaccines or repurpose previously adopted drugs. Challenges in accessing available treatment, inadequate, non-existent, or overstretched healthcare facilities, long COVID disease, cultural practices and beliefs about vaccination, vaccine hesitancy, availability, accessibility and perceived safety of herbal supplements seem to be major factors propelling individuals to use herbal supplements. Published reports advocating for clinical development of herbal supplements for COVID-19 and other emerging and re-emerging viral diseases are sparse. This paper aims to review the pathogenesis of COVID-19, use of herbal products during the pandemic and make case for clinical development of herbal supplements through the adoption of modern and acceptable technologies and research processes. This was a scoping review. Database searches of Google Scholar, PubMed and ResearchGate among others were performed using related keywords to identify relevant journals and lists of primary articles. Clinical trial databases:-Clinicaltrial.gov, Pan African Clinical Trial Registry (PACTR) and WHO international clinical trial registry (ICTRP) were reviewed to extract data. The use of herbal supplements during COVID-19 was not only peculiar to individuals living in Sub-Saharan Africa, but a global practice. Herbal supplements recommended to manage COVID-19 have not been validated using clinical trials. Available data showed that the number of herbal supplements undergoing clinical trial for COVID-19 indication in Africa was low. The availability of medicinal plants in Sub-Saharan Africa if well explored has great potentials to address various emerging and re-emerging viral diseases confronting the region. The economic potential of clinically validated herbal supplements are huge, and tapping into this opportunity created by preference of population to herbal supplement could increase export of herbal supplement and gross domestic product (GDP) of respective countries in Africa.

摘要

2019年冠状病毒病(COVID-19)的出现扰乱了许多国家的卫生系统。人们已努力开发新的治疗方案,如疫苗,或重新利用先前采用的药物。在获取现有治疗方法方面存在挑战、医疗保健设施不足、不存在或不堪重负、长期新冠疾病、关于疫苗接种的文化习俗和信仰、疫苗犹豫、草药补充剂的可获得性、可及性和感知安全性似乎是促使个人使用草药补充剂的主要因素。关于草药补充剂用于COVID-19及其他新出现和再次出现的病毒性疾病的临床开发的已发表报告很少。本文旨在综述COVID-19的发病机制、大流行期间草药产品的使用情况,并通过采用现代且可接受的技术和研究流程为草药补充剂的临床开发提供依据。这是一项范围综述。使用相关关键词在谷歌学术、PubMed和ResearchGate等数据库中进行搜索,以识别相关期刊和原始文章列表。对临床试验数据库——Clinicaltrial.gov、泛非临床试验注册中心(PACTR)和世界卫生组织国际临床试验注册平台(ICTRP)进行了综述以提取数据。COVID-19期间草药补充剂的使用不仅在撒哈拉以南非洲地区的人群中很常见,而是一种全球现象。推荐用于管理COVID-19的草药补充剂尚未通过临床试验验证。现有数据表明,在非洲,针对COVID-19适应症进行临床试验的草药补充剂数量很少。如果对撒哈拉以南非洲地区药用植物的可用性进行充分探索,有很大潜力应对该地区面临的各种新出现和再次出现的病毒性疾病。经过临床验证的草药补充剂的经济潜力巨大,利用民众对草药补充剂的偏好所创造的这一机会,可以增加草药补充剂的出口以及非洲各国的国内生产总值(GDP)。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/96e3/9985929/82b907d851f1/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验